Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated at Stephens

Equities research analysts at Stephens started coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) in a research note issued on Friday, Marketbeat.com reports. The firm set an "equal weight" rating and a $25.00 price target on the stock. Stephens' target price suggests a potential upside of 0.16% from the stock's previous close.

A number of other research analysts also recently issued reports on BCYC. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Cantor Fitzgerald reissued an "overweight" rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Oppenheimer reaffirmed an "outperform" rating and set a $48.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $42.89.

Bicycle Therapeutics Stock Up 1.1 %

BCYC traded up $0.26 during trading hours on Friday, reaching $24.96. 217,301 shares of the company's stock traded hands, compared to its average volume of 356,343. The firm has a 50-day moving average price of $24.39 and a 200 day moving average price of $23.15. The firm has a market capitalization of $1.19 billion, a PE ratio of -7.59 and a beta of 0.89. Bicycle Therapeutics has a 52-week low of $12.54 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business's revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) EPS. Equities analysts predict that Bicycle Therapeutics will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,212 shares of the firm's stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 4,584 shares of company stock worth $102,040 in the last three months. 8.50% of the stock is owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its position in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company's stock valued at $10,001,000 after acquiring an additional 124,809 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company's stock valued at $25,869,000 after purchasing an additional 121,613 shares during the period. TD Asset Management Inc grew its holdings in shares of Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company's stock valued at $1,967,000 after purchasing an additional 42,200 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $11,577,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Bicycle Therapeutics by 275.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 97,392 shares of the company's stock worth $1,971,000 after buying an additional 71,434 shares in the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.